

John Kenneth Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2645412/publications.pdf>

Version: 2024-02-01

211
papers

14,101
citations

28190

55
h-index

22102

113
g-index

215
all docs

215
docs citations

215
times ranked

13695
citing authors

#	ARTICLE	IF	CITATIONS
1	The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 716-725.	0.9	5
2	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <i>Gut</i> , 2022, 71, 1078-1087.	6.1	18
3	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	2.4	22
4	Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 12-17.	0.1	4
5	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	2.4	12
6	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1095-1104.e9.	2.4	21
7	Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1850-1857.	1.1	3
8	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 616-624.	0.6	2
9	Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn's and Colitis Canada. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 105-115.	0.1	8
10	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1011-1019.	0.6	6
11	Ozanimod for the Treatment of Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 2104-2106.	0.6	2
12	Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1151-1159.	1.9	4
13	Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1040-1041.	1.9	1
14	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1555-1564.	0.9	5
15	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 1106-1117.	0.2	28
16	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 208-213.	0.1	6
17	Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. <i>Pharmacoeconomics - Open</i> , 2022, 6, 519-537.	0.9	2
18	A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 48-48.	0.1	8

#	ARTICLE	IF	CITATIONS
19	Clinical Management of the Microbiome in Irritable Bowel Syndrome. Journal of the Canadian Association of Gastroenterology, 2021, 4, 36-43.	0.1	16
20	Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Recurrence: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 451-462.	2.4	26
21	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. Inflammatory Bowel Diseases, 2021, 27, 848-854.	0.9	11
22	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. Journal of Crohn's and Colitis, 2021, 15, 462-470.	0.6	16
23	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.1	2
24	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.1	7
25	Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease. Journal of Medical Systems, 2021, 45, 23.	2.2	14
26	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.1	5
27	Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences. Journal of the Canadian Association of Gastroenterology, 2021, 4, e120-e129.	0.1	3
28	Patients' Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. Clinical and Experimental Gastroenterology, 2021, Volume 14, 123-131.	1.0	7
29	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine, 2021, 47, 521-537.	3.9	148
30	Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity score matched cohort analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2803-2812.	1.4	0
31	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
32	Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2640-2648.	1.4	12
33	The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterology Journal, 2021, 9, 581-589.	1.6	21
34	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ, The, 2021, 374, n1554.	3.0	136
35	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15
36	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) – Part 1: Live Vaccines. Journal of the Canadian Association of Gastroenterology, 2021, 4, e59-e71.	0.1	6

#	ARTICLE	IF	CITATIONS
37	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 2: Inactivated Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e72-e91.	0.1	8
38	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 2: Inactivated Vaccines. <i>Gastroenterology</i> , 2021, 161, 681-700.	0.6	14
39	Stability of diagnostic rate in a cohort of 38,813 colorectal polyp specimens and implications for histomorphology and statistical process control. <i>Scientific Reports</i> , 2021, 11, 16942.	1.6	2
40	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infectionsâ€”A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021, 49, 1558-1566.	0.4	26
41	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
42	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 1: Live Vaccines. <i>Gastroenterology</i> , 2021, 161, 669-680.e0.	0.6	11
43	Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. <i>Gastroenterology</i> , 2021, 161, 1333-1335.e1.	0.6	10
44	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1114-1119.	0.6	9
45	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 874-878.	0.4	1
46	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 24-41.e1.	2.4	40
47	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
48	Efficacy and safety of tofacitinib dose deâ€”escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 271-280.	1.9	65
49	ECCO Guidelines on Therapeutics in Crohnâ€™s Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
50	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.2	23
51	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020, 24, 537.	2.5	36
52	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 997-998.	1.9	2
53	Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2143-2146.	2.4	17
54	Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 800-805.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, e10-e27.	0.1	16
56	Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1676-1682.	1.9	14
57	Clinical trials for coronavirus disease 2019: What is being evaluated and what is not. <i>Annals of Thoracic Medicine</i> , 2020, 15, 49.	0.7	7
58	Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. <i>Intestinal Research</i> , 2020, 18, 430-437.	1.0	30
59	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	0.9	73
60	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	2.4	32
61	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 320-348.	0.6	49
62	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e35-e63.	0.1	16
63	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.1	32
64	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	1.2	6
65	Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1796-1804.	0.9	21
66	Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 178-185.	0.1	3
67	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.1	5
68	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	1.0	22
69	Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 712-717.	0.6	2
70	Effect of age of transfused red blood cells on neurologic outcome following traumatic brain injury (ABLE-tbi Study): a nested study of the Age of Blood Evaluation (ABLE) trial. <i>Canadian Journal of Anaesthesia</i> , 2019, 66, 696-705.	0.7	5
71	Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. <i>Annals of Internal Medicine</i> , 2019, 171, 805.	2.0	310
72	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 50-74.	0.6	87

#	ARTICLE	IF	CITATIONS
73	Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas. <i>Canadian Family Physician</i> , 2019, 65, 784-789.	0.1	9
74	Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. <i>Clinical Therapeutics</i> , 2018, 40, 415-429.e6.	1.1	16
75	Identifying Needs in Young Adults With Inflammatory Bowel Disease. <i>Gastroenterology Nursing</i> , 2018, 41, 19-28.	0.2	8
76	Multidisciplinary damage control management of life-threatening carotid blowout syndrome. <i>Trauma Surgery and Acute Care Open</i> , 2018, 3, e000166.	0.8	1
77	Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 337-347.	2.5	115
78	A Comparison of the Prevalence of Anxiety and Depression Between Uncomplicated and Complex IBD Patient Groups. <i>Gastroenterology Nursing</i> , 2018, 41, 427-435.	0.2	11
79	Journal of the Canadian Association of Gastroenterology. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 1-1.	0.1	0
80	In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not. <i>Annals of Internal Medicine</i> , 2018, 169, JC54.	2.0	0
81	Postinfectious IBS: Defining its clinical features and prognosis using an internet-based survey. <i>United European Gastroenterology Journal</i> , 2018, 6, 1245-1253.	1.6	40
82	Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus. <i>Gastroenterology</i> , 2018, 155, 1325-1347.e3.	0.6	69
83	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 2211.	2.2	22
84	Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1805-1814.	0.8	3
85	Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 191-198.	0.1	2
86	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.1	10
87	Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study. <i>Clinical Therapeutics</i> , 2018, 40, 1024-1032.	1.1	3
88	FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial. <i>BMJ Open</i> , 2018, 8, e022780.	0.8	7
89	Sepsis: frontiers in supportive care, organisation and research. <i>Intensive Care Medicine</i> , 2017, 43, 496-508.	3.9	62
90	Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. <i>Intensive Care Medicine</i> , 2017, 43, 1602-1612.	3.9	143

#	ARTICLE	IF	CITATIONS
91	Sulfasalazine and 5-Aminosalicylates for Ulcerative Colitis. , 2017, , 389-397.		1
92	Reply. Gastroenterology, 2017, 152, 303-304.	0.6	2
93	Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study. Digestive Diseases and Sciences, 2017, 62, 448-455.	1.1	65
94	Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. The Cochrane Library, 2017, 2017, CD009839.	1.5	26
95	Development of the IBD Disk. Inflammatory Bowel Diseases, 2017, 23, 333-340.	0.9	72
96	Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-11.	0.8	22
97	Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. Journal of Blood Medicine, 2016, Volume 7, 239-253.	0.7	5
98	Practice Variation in Spontaneous Breathing Trial Performance and Reporting. Canadian Respiratory Journal, 2016, 2016, 1-10.	0.8	18
99	Clinical practice guideline: management of acute pancreatitis. Canadian Journal of Surgery, 2016, 59, 128-140.	0.5	269
100	Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study. CMAJ Open, 2016, 4, E569-E577.	1.1	9
101	The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 2016, 151, 51-69.e14.	0.6	671
102	Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open, 2016, 6, e010983.	0.8	110
103	Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. American Journal of Gastroenterology, 2016, 111, 477-491.	0.2	151
104	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 2016, 150, 734-757.e1.	0.6	373
105	Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial—PROSPECT: protocol for a feasibility randomized pilot trial. Pilot and Feasibility Studies, 2015, 1, 19.	0.5	16
106	New Applications for Traditional Drugs in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2948-2957.	0.9	3
107	Systematic Review. Inflammatory Bowel Diseases, 2015, 21, 1683-1694.	0.9	64
108	The journey Continues. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 175-175.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Patients and Practice Guidelines: Keeping Eyes on the Horizon. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 290-290.	0.8	0
110	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	0.6	323
111	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 928-935.e2.	2.4	181
112	Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology, 2015, 149, 102-109.e6.	0.6	1,161
113	Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 371-372.	0.8	10
114	Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 66-68.	0.8	35
115	Fecal Occult Blood Testing as a Diagnostic Test in Symptomatic Patients is not Useful: A Retrospective Chart Review. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 421-426.	0.8	27
116	Understanding the Global Epidemiology of Pediatric Critical Illness. Pediatric Critical Care Medicine, 2014, 15, 660-666.	0.2	14
117	Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. Journal of Clinical Epidemiology, 2014, 67, 887-896.	2.4	157
118	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.e6.	0.6	277
119	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 571-581.	0.6	66
120	929c A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis.. Gastroenterology, 2014, 146, S-159.	0.6	17
121	The Origins of Irritable Bowel Syndrome: Experience of a Lifetime. Gastroenterology, 2014, 147, 18-20.	0.6	1
122	Anti-TNF± Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1862-1869.	0.9	69
123	Resource utilization during pediatric to adult transfer of care in IBD. Journal of Crohn's and Colitis, 2013, 7, e55-e60.	0.6	33
124	Bell's palsy in a patient receiving adalimumab for Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, e115.	0.6	5
125	Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 931-936.	1.4	7
126	The Burden of Celiac Disease in Canada: More Work Needed to Lighten the Load. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 448-448.	1.8	2

#	ARTICLE	IF	CITATIONS
127	Fecal Transplant via Retention Enema for Refractory or Recurrent <i>Clostridium difficile</i> Infection. Archives of Internal Medicine, 2012, 172, 191.	4.3	117
128	Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2012, 10, 234-239.	2.4	36
129	Conventional Medical Management of Ulcerative Colitis: Sulfasalazine and 5-Aminosalicylates. , 2012, , 453-466.		1
130	Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. American Journal of Medicine, 2012, 125, 956-962.	0.6	49
131	Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF- α drugs for refractory Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 77-85.	0.6	29
132	Management of inflammatory bowel disease with vitamin D: Beyond bone health. Journal of Crohn's and Colitis, 2012, 6, 397-404.	0.6	54
133	Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane Library, 2012, 11, CD004118.	1.5	29
134	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. American Journal of Gastroenterology, 2012, 107, 179-194.	0.2	142
135	Safety of Esophagogastroduodenoscopy within 30 Days of Myocardial Infarction: A Retrospective Cohort Study from a Canadian Tertiary Centre. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 151-154.	1.8	9
136	An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 593-596.	1.8	20
137	An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Medical Research Methodology, 2012, 12, 15.	1.4	22
138	Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2011, 106, 661-673.	0.2	469
139	Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation. Value in Health, 2011, 14, 263-273.	0.1	30
140	Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2011, 106, 617-629.	0.2	170
141	Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2011, 106, 590-599.	0.2	266
142	Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 373-376.	1.8	12
143	A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2547-2554.	1.3	83
144	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2011, 106, 601-616.	0.2	231

#	ARTICLE	IF	CITATIONS
145	IgG4-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3047-3051.	1.1	26
146	Role of probiotics in management of diverticular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1827-1830.	1.4	24
147	Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 121-125.	1.8	11
148	An Outbreak of Acute Bacterial Gastroenteritis Is Associated With an Increased Incidence of Irritable Bowel Syndrome in Children. <i>American Journal of Gastroenterology</i> , 2010, 105, 933-939.	0.2	93
149	Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2010, , CD004115.	1.5	85
150	Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. <i>Gut</i> , 2010, 59, 605-611.	6.1	189
151	Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis. <i>Gastroenterology</i> , 2010, 138, 1502-1513.	0.6	208
152	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. <i>Gastroenterology</i> , 2010, 138, 1727-1736.	0.6	75
153	Patient outcomes after anti TNF- α drugs for Crohn's disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 163-175.	0.7	14
154	Adherence to Guidelines for Surveillance Colonoscopy in Patients with Ulcerative Colitis at a Canadian Quaternary Care Hospital. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 613-617.	1.8	25
155	Myocardial Infarction, Peptic Ulcer and Acetylsalicylic Acid: Of Good and Evil. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 618-618.	1.8	1
156	Assessing the Educational Needs of Canadian Gastroenterologists and Gastroenterology Nurses: Challenges to Optimal Care in Crohn's Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 805-810.	1.8	9
157	Development and Validation of a Risk Score for Post-Infectious Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009, 104, 2267-2274.	0.2	53
158	Post-infectious irritable bowel syndrome following water contamination. <i>Kidney International</i> , 2009, 75, S42-S43.	2.6	26
159	How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. <i>Health Economics (United Kingdom)</i> , 2009, 18, 1420-1439.	0.8	74
160	Post-infectious irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2009, 15, 3591.	1.4	149
161	Are there epidemiological differences between crohn's disease and ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S1.	0.9	4
162	842 Genetic Risk Factors for Post-Infectious IBS in the Walkerton Outbreak of Waterborne Gastroenteritis. <i>Gastroenterology</i> , 2008, 134, A-122.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn's disease. <i>Evidence-Based Medicine</i> , 2008, 13, 115-115.	0.6	4
164	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 261-272.	1.8	10
165	Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. <i>American Journal of Gastroenterology</i> , 2007, 102, 2047-2056.	0.2	538
166	Postinfectious Irritable Bowel Syndrome After a Food-Borne Outbreak of Acute Gastroenteritis Attributed to a Viral Pathogen. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 457-460.	2.4	224
167	Photodynamic Therapy for Barrett's Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 217-222.	1.8	13
168	Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. <i>Value in Health</i> , 2007, 10, 415-430.	0.1	128
169	Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery. <i>Gastroenterology</i> , 2006, 131, 445-450.	0.6	338
170	A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 421-428.	2.4	34
171	Finding Inflammatory Bowel Disease Genes Will Not Lead to a Cure. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 643-644.	1.8	1
172	Reporting Ileocolonoscopy in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 399-400.	1.8	3
173	Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 38-46.	0.9	249
174	Randomized Active and Placebo-Controlled Endoscopy Study of a Novel Protected Formulation of Oral Alendronate. <i>Digestive Diseases and Sciences</i> , 2006, 51, 864-868.	1.1	12
175	The Incidence of Irritable Bowel Syndrome Among Community Subjects With Previous Acute Enteric Infection. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1026-1032.	1.1	58
176	A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Versus Proton Pump Inhibitors for Treatment of Patients With Chronic Gastroesophageal Reflux Disease: One-Year Follow-Up. <i>Surgical Innovation</i> , 2006, 13, 238-249.	0.4	94
177	The Impact of Reference Pricing of Nonsteroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs. <i>Health Services Research</i> , 2005, 40, 1297-1317.	1.0	29
178	Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults – Update 2004. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 15-35.	1.8	204
179	Long-term Health Sequelae Following E.coli and Campylobacter Contamination of Municipal Water. <i>Canadian Journal of Public Health</i> , 2005, 96, 125-130.	1.1	30
180	Response to "Potentially Flawed Interpretation of Data by Andriulli et al.". <i>American Journal of Gastroenterology</i> , 2005, 100, 2133-2133.	0.2	2

#	ARTICLE	IF	CITATIONS
181	Economic Analysis of Home vs Hospital-Based Parenteral Nutrition in Ontario, Canada. Journal of Parenteral and Enteral Nutrition, 2005, 29, 266-269.	1.3	24
182	CD23-Mediated IgE Transport Across Human Intestinal Epithelium: Inhibition by Blocking Sites of Translation or Binding. Gastroenterology, 2005, 129, 928-940.	0.6	75
183	Talk Is Cheap: The Impact of Consultation. Commentary on the Article. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 181-182.	1.8	0
184	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 503-508.	1.8	25
185	Prospective Comparison of Small Bowel Meal with Pneumocolon versus Ileo-Colonoscopy for the Diagnosis of Ileal Crohn's Disease. American Journal of Gastroenterology, 2004, 99, 1321-1329.	0.2	24
186	Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. Annals of Internal Medicine, 2003, 139, 843.	2.0	458
187	The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opinion on Drug Safety, 2002, 1, 71-78.	1.0	32
188	Use and misuse of cost-effectiveness terminology in the gastroenterology literature: a systematic review. American Journal of Gastroenterology, 2002, 97, 172-179.	0.2	8
189	A Semiquantitative Stool Antigen Test for Helicobacter pylori. Journal of Clinical Gastroenterology, 2002, 35, 369-370.	1.1	0
190	Minimizing postcolonoscopy abdominal pain by using CO2 insufflation: A prospective, randomized, double blind, controlled trial evaluating a new commercially available CO2 delivery system. Gastrointestinal Endoscopy, 2002, 56, 190-194.	0.5	177
191	Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn's Disease: Pearls and Pitfalls. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 877-879.	1.8	1
192	Resource Utilization for Acute Lower Gastrointestinal Hemorrhage: The Ontario GI Bleed Study. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 677-682.	1.8	38
193	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health, 2002, 5, 312-328.	0.1	26
194	Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Cmaj, 2002, 166, 1655-62.	0.9	23
195	14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. Journal of Rheumatology, 2002, 29, 1965-74.	1.0	44
196	Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis. Pharmacoeconomics, 2001, 19, 1039-1049.	1.7	41
197	Epidemiological Aspects of Irritable Bowel Syndrome in Europe and North America. Digestion, 2001, 64, 200-204.	1.2	86
198	A Critical Approach to Clinical Practice Guidelines. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 505-509.	1.8	9

#	ARTICLE	IF	CITATIONS
199	Test-and-Treat Strategies for <i>Helicobacter pylori</i> in Uninvestigated Dyspepsia: A Canadian Economic Analysis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 379-388.	1.8	26
200	Putting Rectal 5-Aminosalicylic Acid in Its Place: The Role in Distal Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 1628-1636.	0.2	111
201	Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. <i>Gastroenterology</i> , 2000, 119, 1740-1744.	0.6	253
202	Prediction of Resource Utilization and Case Cost for Acute Nonvariceal Upper Gastrointestinal Hemorrhage at A Canadian Community Hospital. <i>American Journal of Gastroenterology</i> , 1999, 94, 1841-1846.	0.2	33
203	Marked Elevation of Serum Transaminases May Be Associated With Ovarian Hyperstimulation Syndrome. <i>American Journal of Gastroenterology</i> , 1999, 94, 3373.	0.2	9
204	Lymphocytic and collagenous colitis: Medical management. Current Treatment Options in <i>Gastroenterology</i> , 1999, 2, 127-133.	0.3	10
205	Demographic Predictors of Resource Utilization for Bleeding Peptic Ulcer Disease: The Ontario GI Bleed Study. <i>Journal of Clinical Gastroenterology</i> , 1999, 29, 165-170.	1.1	13
206	Ketotifen Treatment of Active Colitis in Patients with 5-Aminosalicylate Intolerance. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1998, 12, 273-275.	1.8	27
207	Omeprazole for Refractory Gastroesophageal Reflux Disease during Pregnancy and Lactation. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1998, 12, 225-227.	1.8	34
208	Terminal Ileal Imaging With Ileoscopy Versus Small-Bowel Meal With Pneumocolon. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 217-222.	1.1	17
209	Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 521-525.	0.8	40
210	Successful Therapy of Refractory Erythema Nodosum Associated with Crohn's Disease Using Potassium Iodide. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1997, 11, 501-502.	1.8	24
211	Fecal transplantation for recurrent or refractory <i>Clostridium difficile</i> diarrhea. <i>The Cochrane Library</i> , 0, , .	1.5	0